Hormonal Infertility Market is Segmented By Drug Class (Direct thrombin inhibitors, Direct factor Xa inhibitors, Others), By Indication(Atrial fibrillation (AF), Nonvalvular atrial fibrillation (AF), Deep vein thrombosis, Others), By Distribution Channel(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Treatment(Medications, Surgery, Assisted Reproductive Technology, Others), By Diseases(Polycystic Ovary Syndrome, Pituitary Tumors, Diabetes, Menopause, Cushing’s Syndrome, STDs, Polyps & Fibroids, Others), By Treatment Sales(End-User, Distribution Channel, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029.
Hormonal Infertility Market is Segmented to reach at a CAGR 10.05% during the forecast period (2022-2029).
Hormonal infertility is a condition in which hormonal decline and imbalance are natural occurrences that can cause physical, mental, and emotional problems. Infertility is the inability of a sexually active couple unsuccessful in trying to conceive over one full year without taking any birth control pills. When the causes are present in females, it is referred to as female infertility.
Hormonal Infertility Market
|
Metrics |
Details |
|
Market CAGR |
10.05% |
|
Segments Covered |
By Drug Class, By Indication, By Distribution Channel, By Treatment, By Diseases, By Treatment Sales, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
To Get a Free Sample Click here
Hormonal Infertility Market Dynamics
The global hormonal infertility market growth is driven by the rising prevalence of reproductive hormones diseases worldwide and emerging markets are responsible for the growth of this market. Increased use of alcohol, drugs use, increased use of birth control pills, and increased awareness towards female reproductive health also boost the hormonal infertility market.
Robust pipeline drugs coupled with the increasing prevalence of hormonal diseases are expected to drive the market growth
Growing cases of fluctuating hormone levels drive the hormonal infertility market. Several reasons can cause hormonal infertility in females, such as irregular or absent menstrual periods, lowered levels of LH and FSH, damage in reproductive organ (including; fallopian tubes, uterus & cervix), presence of diseases (such as; tumor, cyst, STDs or congenital disabilities), stress and alcohol and drugs use will also boost up the hormonal infertility market.
Polycystic ovary syndrome (PCOS) is a common hormonal endocrine disorder that affects women of childbearing age (15 to 49 years). According to the Centers for Disease Control & Prevention (CDC), PCOS is the most common cause of female infertility. Also, as per a study published in September 2019, the prevalence of polycystic ovarian syndrome in adolescents, based on the Rotterdam criteria, was found to be 11.04%, based on the National Institute of Health’s criteria was 3.39%, and based on the Androgen Excess and Polycystic Ovary Syndrome Society was 8.03%, worldwide. Moreover, the players in the market are currently focusing on the unmet need of the market and on strengthening their pipelines to leverage the opportunities; the commercialization of these robust pipelines is expected to propel market growth. For instance, Forendo Pharma, a clinical-stage drug development company focusing on novel treatments in women’s health, currently has the molecule HSD17B5 inhibitor in its pipeline. This enzyme is overexpressed in the adipose tissue of PCOS patients. Such developments are expected to boost the market over the forecast period.
Lack of female reproductive health awareness is likely to restrain the market growth
Lack of female reproductive health awareness in developing countries may hamper the global hormonal infertility market. There is a lack of awareness regarding reproductive health in India due to illiteracy and ignorance. There are weird social customs and taboo, shyness. Many traditions make people secretive about reproductive health, and thus, the problems spread far and wide are likely to hamper the market growth.
COVID-19 Impact Analysis
Due to the pandemic, various gynecological procedures and unnecessary treatment have been postponed. Furthermore, non-COVID-19 related research is being delayed by various companies, leading to delayed product launches. Some disruptions in sourcing raw materials from impacted countries, such as China, were observed in early 2020, but such disorders are unlikely to affect going forward.
Hormonal Infertility Market Segment Analysis
The aromatase inhibitors segment is expected to hold the largest share in this market segment
Aromatase inhibitors are a class of medicines that work by blocking the enzyme aromatase, the enzyme that converts androgens into estrogen. Letrozole is a non-steroidal, highly selective oral aromatase inhibitor (AI), which can reversibly bind to the rate-limiting enzyme P450 aromatase in the estrogen biosynthesis pathway and inhibit the conversion of testosterone to estradiol and androstenedione to estrone.
Hormonal Infertility Market Geographical Analysis
North America region holds the largest market share of the global hormonal infertility market
North America region holds the largest market share of the global hormonal infertility market, owing to the high prevalence of polycystic ovary syndrome (PCOS) in the U.S. For instance, according to the Centers for Disease and Disease Control Prevention 2019, PCOS is one of the most common causes of female infertility, affecting 6 to 12% (as many as 5 million) women of reproductive age in the U.S. Moreover, more than half of the women with PCOS develop type 2 diabetes by age 40.
Obesity, considered one of the major risk factors for hormonal infertility, has increased during the pandemic. In September 2020, the Centers for Disease Control and Prevention (CDC) notified that adult obesity is increasing, and racial and ethnic disparities persist due to the current circumstances of work from home, lesser physical activities, and financial and other stress among the adult population. The CDC stated that obesity remains high, and currently, twelve states have an adult obesity prevalence at or above 35 %, including Alabama, Arkansas, Indiana, Kansas, Kentucky, Louisiana, Michigan, Mississippi, Oklahoma, South Carolina, Tennessee, and West Virginia. The data by CDC revealed that there is a high prevalence of obesity in North American countries, which is going to increase the risk of hormonal infertility and is anticipated to offer positive growth to the market.
Hormonal Infertility Market Competitive Landscape
The global hormonal infertility market is moderately competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Par Pharmaceutical, TerSera Therapeutics LLC, Merck & Co. Inc, Teva Pharmaceuticals, AbbVie Inc, Sanofi S.A, Incepta Pharmaceuticals Ltd., Serum Institute of India Pvt. Ltd and among others.
Global Hormonal Infertility Market – Key Companies to Watch
Merck & Co. Inc
Overview: Merck & Co., Inc. is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. The Company’s operations are principally managed on a product basis and include two operating segments, which are the pharmaceutical and animal health segments, both of which are reportable. The pharmaceutical segment includes human health pharmaceutical and vaccine products.
Product Portfolio: It includes products like GONAL-f (follitropin alfa for injection), Ovidrel Prefilled Syringe (choriogonadotropin alfa injection) and Cetrotide (cetrorelix acetate for injection).
Frequently Asked Questions
What is the Projected CAGR value of the Hormonal Infertility Market?
Hormonal Infertility Market is expected to grow at a CAGR of 10.05% during the forecasting period 2022-2029.
Which region controlled the global market during 2022-2029?
North America region Controls the Hormonal Infertility Market during 2022-2029
Which is the fastest growing region in the Hormonal Infertility Market?
Among all regions, Asia Pacific is the fastest growing market share during the forecast period
Trending Topics
Gonadotropin-Releasing Hormone (GnRH) Agonists and Antagonists Drugs Market